Overview
- Humacyte priced an underwritten offering Thursday of 47,619,048 shares at $1.05 per share for expected gross proceeds of about $50 million and granted underwriters a 30-day option to buy up to 7,142,857 additional shares.
- The offering is a primary sale managed by Barclays, BTIG and Titan Partners and is expected to close on or about June 12, 2026 subject to customary closing conditions and final SEC filings.
- Humacyte says net proceeds will be used to commercialize Symvess, prepare a Biologics License Application supplement for a hemodialysis indication, advance its pipeline programs, and support working capital and general corporate needs.
- The company reported a positive interim readout from its Phase 3 V012 study showing ATEV patients averaged 220 catheter-free days versus 129 days for AV fistula patients (p=0.00070) and a lower reported infection rate for ATEV recipients, and it plans to seek a BLA supplement in the second half of 2026.
- Symvess is Humacyte’s first FDA-approved product, commercially launched in the U.S. in Q1 2025, and the offering is being made from a shelf registration the company filed in September 2025; shares fell sharply in early trading after the announcements.